HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 374 participants.
Also called NCT03550859
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 374 participants
- Sponsor
- Registry
-
NCT03550859
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT03550859. Randomized; no masking; primary purpose treatment. Start 2018-06-05 (actual); primary completion 2021-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
- Condition
- Chronic Kidney Disease
- Condition
- Proteinuria
- Intervention (Drug)
- Telmisartan/Rosuvastatin 40/10mg
- Intervention (Drug)
- Telmisartan 40mg
- Lead sponsor
- Yuhan Corporation
Record details
- Record id
cardio:ct-nct03550859- Content hash
5fc8f701fcb01792cf720788b5e15ca9fa45306a0245db1e0d0335b0462d849e